Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Abstract RIP2 kinase has been identified as a key signal transduction partner in the NOD2 pathway contributing to a variety of human pathologies, including immune-mediated inflammatory diseases. Small-molecule inhibitors of RIP2 kinase or its signaling partners on the NOD2 pathway that are suitable for advancement into the clinic have yet to be described. Herein, we report our discovery and profile of the prodrug clinical compound, inhibitor 3, currently in phase 1 clinical studies. Compound 3 potently binds to RIP2 kinase with good kinase specificity and has excellent activity in blocking many proinflammatory cytokine responses in vivo and in human IBD explant samples. The highly favorable physicochemical and ADMET properties of 3 combined with high potency led to a predicted low oral dose in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NOD proteins: regulators of inflammation in health and disease
Philpott, D. J., Sorbara, M. T., Robertson, S. J., Croitoru, K., & Girardin, S. E. (2014) · Nature Reviews Immunology · doi:10.1038/nri3565 · Cited by 668
Research works printed but not linked: 22
- Takeuchi, 2010, Pattern recognition receptors and inflammation, Cell, 140, 805, 10.1016/j.cell.2010.01.022 · DOI · Paper page
- Biswas, 2010, Induction and rescue of Nod2-dependent Th1-driven granulomatous inflammation of the ileum, Proc. Natl. Acad. Sci. U. S. A., 107, 14739, 10.1073/pnas.1003363107 · DOI · Paper page
- Jamontt, 2013, Nucleotide-binding oligomerization domain 2 signaling promotes hyperresponsive macrophages and colitis in IL-10-deficient mice, J. Immunol., 190, 2948, 10.4049/jimmunol.1201332 · DOI
- Foley, 2013, OR3-001 – RIP2 kinase is activated in Blau Syndrome and IBD, Pediatric Rheumatology, 11, A3, 10.1186/1546-0096-11-S1-A3 · doi:10.1186/1546-0096-11-s1-a3
- Sfriso, 2012, Blau syndrome, clinical and genetic aspects, Autoimmun. Rev., 12, 44, 10.1016/j.autrev.2012.07.028 · DOI
- Ospelt, 2009, Expression, regulation, and signaling of the pattern-recognition receptor nucleotide-binding oligomerization domain 2 in rheumatoid arthritis synovial fibroblasts, Arthritis Rheum., 60, 355, 10.1002/art.24226 · DOI
- Rosenzweig, 2010, Nucleotide-binding oligomerization domain 2 and Toll-like receptor 2 function independently in a murine model of arthritis triggered by intraarticular peptidoglycan, Arthritis Rheum., 62, 1051, 10.1002/art.27335 · DOI
- Gatheral, 2012, A key role for the endothelium in NOD1 mediated vascular inflammation: comparison to TLR4 responses, PLoS One, 7, 10.1371/journal.pone.0042386 · DOI
- Schirbel, 2013, Pro-angiogenic activity of TLRs and NLRs: a novel link between gut microbiota and intestinal angiogenesis, Gastroenterology, 144, 613, 10.1053/j.gastro.2012.11.005 · DOI · Paper page
- Hugot, 2001, Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease, Nature, 411, 599, 10.1038/35079107 · DOI · Paper page
- Haile, 2016, The identification and pharmacological characterization of 6-(tert-butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a highly potent and selective inhibitor of RIP2 kinase, J. Med. Chem., 59, 4867, 10.1021/acs.jmedchem.6b00211 · DOI · Paper page
- Haile, 2018, Identification of quinoline-based RIP2 kinase inhibitors with an improved therapeutic index to the hERG ion channel, ACS Med. Chem. Lett., 9, 1039, 10.1021/acsmedchemlett.8b00344 · DOI
- Nachbur, 2015, A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production, Nat. Commun., 6, 6442, 10.1038/ncomms7442 · DOI · Paper page
- Canning, 2015, Inflammatory signaling by NOD-RIPK2 is inhibited by clinically relevant type II kinase inhibitors, Chem. Biol., 22, 1174, 10.1016/j.chembiol.2015.07.017 · DOI
- Tigno-Aranjuez, 2014, In vivo inhibition of RIPK2 kinase alleviates inflammatory disease, J. Biol. Chem., 289, 29651, 10.1074/jbc.M114.591388 · DOI · Paper page
- Heimbach, 2003, Enzyme-mediated precipitation of parent drugs from their phosphate prodrugs, Int. J. Pharm., 261, 81, 10.1016/S0378-5173(03)00287-4 · doi:10.1016/s0378-5173(03)00287-4
- Abbott, 2007, Coordinated regulation of Toll-like receptor and NOD2 signaling by K63-linked polyubiquitin chains, Mol. Cell. Biol., 27, 6012, 10.1128/MCB.00270-07 · DOI · Paper page
- Antoniou, 2016, The TNBS-induced colitis animal model: An overview, Annals of medicine and surgery (2012), 11, 9, 10.1016/j.amsu.2016.07.019 · DOI · Paper page
- Vossenkamper, 2014, A CD3-specific antibody reduces cytokine production and alters phosphoprotein profiles in intestinal tissues from patients with inflammatory bowel disease, Gastroenterology, 147, 172, 10.1053/j.gastro.2014.03.049 · DOI
- Fritz, 2005, Synergistic stimulation of human monocytes and dendritic cells by Toll-like receptor 4 and NOD1- and NOD2-activating agonists, Eur. J. Immunol., 35, 2459, 10.1002/eji.200526286 · DOI · Paper page
- van Heel, 2005, Synergistic enhancement of Toll-like receptor responses by NOD1 activation, Eur. J. Immunol., 35, 2471, 10.1002/eji.200526296 · DOI · Paper page
- Pashenkov, 2019, Synergistic interactions between NOD receptors and TLRs: Mechanisms and clinical implications, J. Leukocyte Biol., 105, 669, 10.1002/JLB.2RU0718-290R · DOI
Cited by
Pathway paradigms revealed from the genetics of inflammatory bowel disease
Graham, D. B., & Xavier, R. J. (2020) · Nature · doi:10.1038/s41586-020-2025-2 · Cited by 771
Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2
Mares, A., Miah, A. H., Smith, I. E. D., Rackham, M., Thawani, A. R., Cryan, J., Haile, P. A., Votta, B. J., Beal, A. M., Capriotti, C., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-0868-6 · Cited by 232
Self-citationRecent advances in the development of RIPK2 modulators for the treatment of inflammatory diseases
Pham, A.-T., Ghilardi, A. F., & Sun, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1127722 · Cited by 40
“, quinoline to quinazoline; indazole to benzothiazole) resulted in the 4-aminoquinazoline series (4, Figure 6; Figure 7D) that had a divergent structure-activity relationship (SAR) in inhibitory activities for RIPK2 and hERG ion channel (Haile et al., 2019).”
BackgroundStructure shows that the BIR2 domain of E3 ligase XIAP binds across the RIPK2 kinase dimer interface
Lethier, M., Huard, K., Hons, M., Favier, A., Brutscher, B., Boeri Erba, E., Abbott, D. W., Cusack, S., & Pellegrini, E. (2023) · Life Science Alliance · doi:10.26508/lsa.202201784 · Cited by 11
Metadata
- Authors
- Haile, P. A., Casillas, L. N., Votta, B. J., Wang, G. Z., Charnley, A. K., Dong, X., Bury, M. J., Romano, J. J., Mehlmann, J. F., King, B. W., Erhard, K. F., Hanning, C. R., Lipshutz, D. B., Desai, B. M., Capriotti, C. A., Schaeffer, M. C., Berger, S. B., Mahajan, M. K., Reilly, M. A., Nagilla, R., Rivera, E. J., Sun, H. H., Kenna, J. K., Beal, A. M., Ouellette, M. T., Kelly, M., Stemp, G., Convery, M. A., Vossenkämper, A., MacDonald, T. T., Gough, P. J., Bertin, J., & Marquis, R. W.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2019-07-02
- Volume
- 62
- Issue
- 14
- Pages
- 6482-6494
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W4252067953
- Cited by
- 63
- References
- 1
- FWCI
- 2.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- GlaxoSmithKline (NA)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases. https://app.cochat.ai/papers/10.1021/acs.jmedchem.9b00575
- The paper
- Haile, P. A., Casillas, L. N., Votta, B. J., Wang, G. Z., Charnley, A. K., Dong, X., Bury, M. J., Romano, J. J., Mehlmann, J. F., King, B. W., Erhard, K. F., Hanning, C. R., Lipshutz, D. B., Desai, B. M., Capriotti, C. A., Schaeffer, M. C., Berger, S. B., Mahajan, M. K., Reilly, M. A., . . . Marquis, R. W. (2019). Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.9b00575
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.